Acute Systemic Complications Following High-Dose Semaglutide Reinitiation in an Elderly Patient.
Clin Case Rep · 2026
Last updated 2026-08-28| Journal | Clin Case Rep, 2026 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide |
Abstract
Severe gastrointestinal intolerance with systemic complications can occur within hours of reinitiating high-dose semaglutide after a prolonged treatment interruption, even in patients who previously tolerated the medication. Elderly patients with comorbidities may be particularly vulnerable. Clinicians should consider re-titration from lower doses when restarting GLP-1 receptor agonists after drug holidays to minimize severe adverse effects.
Verbatim abstract via PubMed 42038657 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.